Volume 28, Number 1—January 2022
Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
|PCV7||4, 6B, 9V, 14, 18C, 19F, and 23F|
|PCV10 non-7 (in PCV10 and not PCV7)||1, 5, and 7F|
|PCV13 non-10 (in PCV13 and not PCV10)||3, 6A, and 19A|
|Non-PCV10||Any serotype not in PCV10|
|Non-PCV13||Any serotype not in PCV13|
|PPV23 non-PCV13 (in PPV23 and not PCV13)||2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F|
|Nonvaccine (not in PCV13 or PPV23)
||Any serotype not in PCV13 and not in PPV23
|PCV15 non-13 (in PCV15 and not PCV13)||22F and 33F|
|PCV20 non-13 (in PCV20 and not PCV13)||8, 10A, 11A, 12F, 15B, 22F and 33F|
*PCV, pneumococcal conjugate vaccine; PCV7, 7-valent pneumococcal conjugate vaccine; PCV10, 10-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine.
1Members of the SpIDnet group who contributed are listed at the end of this article.